Advertisement
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
No AccessJournal of UrologyAdult Urology1 Sep 2017

Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE

    View All Author Information

    Purpose:

    We determined whether decreased peak urine flow is associated with future incident lower urinary tract symptoms in men with mild to no lower urinary tract symptoms.

    Materials and Methods:

    Our population consisted of 3,140 men from the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial with mild to no lower urinary tract symptoms, defined as I-PSS (International Prostate Symptom Score) less than 8. REDUCE was a randomized trial of dutasteride vs placebo for prostate cancer prevention in men with elevated prostate specific antigen and negative biopsy. I-PSS measures were obtained every 6 months throughout the 4-year study. The association between peak urine flow rate and progression to incident lower urinary tract symptoms, defined as the first of medical treatment, surgery or sustained and clinically significant lower urinary tract symptoms, was tested by multivariable Cox models, adjusting for various baseline characteristics and treatment arm.

    Results:

    On multivariable analysis as a continuous variable, decreased peak urine flow rate was significantly associated with an increased risk of incident lower urinary tract symptoms (p = 0.002). Results were similar in the dutasteride and placebo arms. On univariable analysis when peak flow was categorized as 15 or greater, 10 to 14.9 and less than 10 ml per second, flow rates of 10 to 14.9 and less than 10 ml per second were associated with a significantly increased risk of incident lower urinary tract symptoms (HR 1.39, p = 0.011 and 1.67, p <0.001, respectively). Results were similar on multivariable analysis, although in the 10 to 14.9 ml per second group findings were no longer statistically significant (HR 1.26, p = 0.071).

    Conclusions:

    In men with mild to no lower urinary tract symptoms a decreased peak urine flow rate is independently associated with incident lower urinary tract symptoms. If confirmed, these men should be followed closer for incident lower urinary tract symptoms.

    References

    • 1 : Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol2012; 62: 234. Google Scholar
    • 2 : Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. BJU Int2005; 95: 810. Google Scholar
    • 3 : Lower urinary tract symptoms increase the risk of falls in older men. BJU Int2009; 104: 63. Google Scholar
    • 4 : The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol2001; 39: 390. Google Scholar
    • 5 : Benign prostatic hyperplasia: a progressive disease of aging men. Urology2003; 61: 267. Google Scholar
    • 6 : Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol2006; 175: 1422. LinkGoogle Scholar
    • 7 : Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int2014; 113: 623. Google Scholar
    • 8 : Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol1995; 153: 1510. LinkGoogle Scholar
    • 9 : Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology2001; 58: 210. Google Scholar
    • 10 : Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol1999; 162: 376. LinkGoogle Scholar
    • 11 : BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int2008; 101: 17. Google Scholar
    • 12 : Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol2002; 42: 1. Google Scholar
    • 13 : Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol2009; 181: 710. LinkGoogle Scholar
    • 14 : Effect of dutasteride on the risk of prostate cancer. N Engl J Med2010; 362: 1192. Google Scholar
    • 15 : Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH. Eur Urol2001; 40: 13. Google Scholar
    • 16 : Does prostate size predict the development of incident lower urinary tract symptoms in men with mild to no current symptoms? Results from the REDUCE trial. Eur Urol2016; 69: 885. Google Scholar
    • 17 : Natural history of prostatism: risk factors for acute urinary retention. J Urol1997; 158: 481. LinkGoogle Scholar
    • 18 : Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment. Int J Urol2010; 17: 69. Google Scholar
    • 19 : Correlation of prostatic urethral angle with the severity of urinary symptom and peak flow rate in men with small prostate volume. PLoS One2014; 9: e104395. Google Scholar
    • 20 : Prostatic urethral angle might be a predictor of treatment efficacy of alpha-blockers in men with lower urinary tract symptoms. Drug Des Devel Ther2014; 8: 937. Google Scholar
    • 21 : Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol2012; 188: 1375. LinkGoogle Scholar
    • 22 : The cost of preoperative urodynamics: a secondary analysis of the ValUE trial. Neurourol Urodyn2016; 35: 81. Google Scholar
    Advertisement